Offices of Howard G. Smith announces that a class action lawsuit has
been filed in the United States District Court for the Southern District
of New York on behalf of all persons and/or entities who purchased or
otherwise acquired the ordinary shares of Prosensa Holding N.V.
("Prosensa" or the "Company") (NASDAQ:RNA) pursuant and/or traceable to
the Registration Statement and Prospectus (collectively, the
"Registration Statement") issued in connection with the Company's
initial public offering ("IPO") on or about June 28, 2013.
Prosensa is a biotechnology company engaged in he discovery and
development of RNA-modulating therapeutics for the treatment of genetic
disorders. The Company's first and lead product candidate was
drisapersen, which Prosensa was developing in collaboration with
GlaxoSmithKline to address a variety of mutations resulting in
inadequate production of dystrophin - a protein necessary for muscle
function. The Complaint alleges that the Registration Statement
contained materially false and/or misleading statements and/or omitted
material information concerning the development status of drisapersen,
the drug's Phase II and Phase III clinical studies, and the prospects
for drisapersen's regulatory approval.
If you are a member of the Class described above, you have until
September 16, 2014, to move the Court to serve as lead plaintiff, if you
meet certain legal requirements. To be a member of the Class you need
not take any action at this time; you may retain counsel of your choice
or take no action and remain an absent member of the Class. If you wish
to learn more about this action, please contact Howard G. Smith,
Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite
112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll
Free at (888) 638-4847, or by email to email@example.com,
or visit our website at http://www.howardsmithlaw.com.
[ Back To NFVZone's Homepage ]